Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    24
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AX04 LEDOBOOK 15 G Lenalidomide - 15mg 15mg Capsule 62,230,245 L.L
M05BA04 APO-ALENDRONATE G Alendronate (monosodium trihydrate) - 70mg 70mg Tablet 1,173,175 L.L
N05AX12 ABIPREX 15 G Aripiprazole - 15mg 15mg Tablet 1,075,074 L.L
R05DB13 TUSSIN G Butamirate citrate - 7.5mg/5ml 7.5mg/5ml Syrup, sugar free 154,862 L.L
V03AC03 DEFEROXAL 90 G Deferasirox - 90mg 90mg Tablet, film coated 9,279,724 L.L
A02BC02 GASTROPAN G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 1,104,639 L.L
A08AB01 ORLY SLIM G Orlistat - 120mg 120mg Capsule 1,174,518 L.L
A11CC05 EURO D HP 50.000 IU G Vitamin D3 - 50,000IU 50,000IU Capsule 1,261,868 L.L
B05XA03 SODIUM CHLORIDE INJECTION/ DEMO G Sodium chloride - 0.9% w/v 0.9% w/v Injectable solution 1,419,098 L.L
C07AB03 ATONIUM G Atenolol - 100mg 100mg Tablet 461,207 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet 579,196 L.L
G01AF02 CANAGYN G Clotrimazole - 500mg 500mg Tablet 302,365 L.L
H02AB02 DEXAMED G Dexamethasone - 8mg/2ml 8mg/2ml Injectable solution 338,648 L.L
J01DD08 CEFIXIME NEOCEF G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Suspension 692,079 L.L
J02AC01 STABILANOL G Fluconazole - 150mg 150mg Capsule 240,979 L.L
L01XA02 CARBOPLATIN VIANEX G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution 1,277,994 L.L
L04AX04 SOTIRA G Lenalidomide - 15mg 15mg Capsule 76,208,289 L.L
M05BA04 MARVIL 70 G Alendronate (monosodium trihydrate) - 70mg 70mg Tablet, coated 1,173,175 L.L
N03AX09 LAMOTRIGINE NORMON G Lamotrigine - 100mg 100mg Tablet, dispersible/ chewable 2,284,532 L.L
N05AX12 PIRIFY G Aripiprazole - 15mg 15mg Tablet 795,555 L.L
V03AC03 DEFERASIROX ARROW G Deferasirox - 90mg 90mg Tablet 8,846,092 L.L
A02BC02 GASTROPAN G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 581,884 L.L
A08AB01 ELIZA 120 G Orlistat - 120mg 120mg Capsule 1,711,159 L.L
A11CC05 BIODAL G Vitamin D3 - 50,000IU 50,000IU Tablet, film coated 1,110,014 L.L
B05XA03 SODIUM CHLORIDE INJECTION/ DEMO G Sodium chloride - 0.9% w/v 0.9% w/v Injectable solution 567,102 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 400mg 400mg Tablet, coated 615,480 L.L
C09DA03 VIOSTAN PLUS 160/25 G Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet, film coated 671,921 L.L
G01AF02 MICOTER GYNO OVULE G Clotrimazole - 500mg 500mg Pessary 447,948 L.L
H02AB02 DEXAMEDIS FORT G Dexamethasone Phosphate - 8mg/2ml 8mg/2ml Injectable solution 43,003 L.L
J01DD08 MUREX G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 528,130 L.L
    ...
    24
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025